Amgen's all grown up now, paying dividends

Amgen, with several major drugs already to market, is more like a big pharma company at this point than your classic biotech firm burning through cash while working toward a breakthrough, the Wall Street Journal says. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.